the NK cells used in this phase 1 trial are not even going to be used the same way or at all in the future trials I believe. They are enhancing it, using them in a combination study and also developing CaR-NK cells…
But as you correctly say, to see 1/3 CR, even if the sustained CR was partially attributed to consolidation therapy, it doesn’t matter- the fact is the CR occurred prior to consolidation therapy, which is standard of care anyway so you would expect patients to do that in the real world.
I’ll continue to follow the science and so far it is compelling across many fronts for CHM.
CHM Price at posting:
15.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)